COT Cotinga Pharmaceuticals Inc

Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that
it has received acceptance from the TSX Venture Exchange ("TSXV") to extend the
expiry term of 1,575,500 common share purchase warrants ("Warrants") issued as
part of its private placement in April and May 2010 representing the third
amendment made for these warrants. 


"This amendment recognizes the additional potential financing source for the
Company represented by these warrants that can be retained at a relatively low
cost," said Dr. Wayne Danter, President and Chief Executive Officer. "It also
acknowledges the long term support from our investors in the original private
placement related to these warrants."


Prior to this amendment, each Warrant entitled its holder to purchase one common
share of the Company at an exercise price of $0.37 per share (other than 129,019
Warrants held by insiders of the Company exercisable at $0.55 per share). The
Expiry Date of the Warrants is March 14, 2014, which date may be reduced to a
period of 14 days (other than for the 129,019 warrants held by insiders of the
company) if, for any ten consecutive trading days during the unexpired term of
the Warrant (the "Premium Trading Days"), the closing price of the common shares
equals or exceeds $0.55. The reduced exercise period of 14 days begins seven
calendar days after the tenth Premium Trading Day.


The Expiry Date is now being amended to extend it to 5:00 p.m. EST on March 31,
2015, (the "New Expiry Date"). All other previously amended and unamended terms
and conditions of the Warrants remain unchanged. The Company will deliver a
Notice of Amendment reflecting the amended expiry date to the registered holders
of the Warrants.


About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge technology company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI'S proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com


www.twitter.com/CriticalOutcome
www.criticaloutcome.com

Cotinga Pharmaceuticals (TSXV:COT)
Historical Stock Chart
From Dec 2024 to Jan 2025

Cotinga Pharmaceuticals (TSXV:COT)
Historical Stock Chart
From Jan 2024 to Jan 2025